Keapstone Therapeutics

About:

Keapstone Therapeutics provides drug development and neurodegeneration services.

Top Investors: Parkinson's UK

Description:

Keapstone Therapeutics provides drugs targeting, biotechnology research, amyotrophic lateral sclerosis, fatal neurodegenerative, healthcare, consulting, fasciculations, and translational neuroscience services.

Total Funding Amount:

2.4M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Sheffield, Sheffield, United Kingdom

Founded Date:

2017-01-01

Contact Email:

info(AT)keapstone.com

Founders:

Pamela Shaw, Richard Mead

Number of Employees:

1-10

Last Funding Date:

2018-09-25

IPO Status:

Private

Industries: